We have located links that may give you full text access.
Mifepristone Implementation in Primary Care: Clinician and Staff Insights from a Pilot Learning Collaborative.
Contraception 2023 September 11
OBJECTIVES: The ExPAND Mifepristone learning collaborative (ExPAND) aims to support community-based primary care providers in overcoming logistical barriers to mifepristone provision. This qualitative study describes clinician and staff perspectives on the impact of ExPAND in two federally qualified health center networks (FQHCs).
STUDY DESIGN: Researchers interviewed a purposive sample of clinicians, staff members, and clinic leaders from two participating Illinois FQHCs using an interview guide grounded in the Consolidated Framework for Implementation Research. We analyzed interview transcripts in batches using grounded theory to identify themes regarding the reception of ExPAND, and barriers to and facilitators of program implementation.
RESULTS: Participants (n=13) expressed strong support for the provision of mifepristone for miscarriage management at their clinic sites. Generally, they personally supported mifepristone for both miscarriage management and abortion care. Many participants felt that ExPAND reflected their clinics' values as it strengthens the primary care relationship, focuses on patient-centered care, and addresses disparities in access. Some barriers to implementation include a fear that providing abortion care would jeopardize FQHC funding, as well as logistical hurdles due to the COVID-19 pandemic.
CONCLUSIONS: Participants felt that providing mifepristone in primary care settings was an important service for their patients and that ExPAND helped achieve that goal. The learning collaborative model can be used to support FQHCs incorporating miscarriage and abortion care. The findings of this study emphasize that in the future, clinics participating in ExPAND would benefit from education around how FQHCs can provide mifepristone for abortion care while complying with federal funding restrictions.
IMPLICATIONS STATEMENT: Learning collaboratives like ExPAND Mifepristone can help prepare primary care clinics to provide mifepristone. Clinicians and staff describe a clear benefit of mifepristone integration to their patient populations. Participants report mifepristone integration aligns with clinic values around patient-centered care and improved access to care.
STUDY DESIGN: Researchers interviewed a purposive sample of clinicians, staff members, and clinic leaders from two participating Illinois FQHCs using an interview guide grounded in the Consolidated Framework for Implementation Research. We analyzed interview transcripts in batches using grounded theory to identify themes regarding the reception of ExPAND, and barriers to and facilitators of program implementation.
RESULTS: Participants (n=13) expressed strong support for the provision of mifepristone for miscarriage management at their clinic sites. Generally, they personally supported mifepristone for both miscarriage management and abortion care. Many participants felt that ExPAND reflected their clinics' values as it strengthens the primary care relationship, focuses on patient-centered care, and addresses disparities in access. Some barriers to implementation include a fear that providing abortion care would jeopardize FQHC funding, as well as logistical hurdles due to the COVID-19 pandemic.
CONCLUSIONS: Participants felt that providing mifepristone in primary care settings was an important service for their patients and that ExPAND helped achieve that goal. The learning collaborative model can be used to support FQHCs incorporating miscarriage and abortion care. The findings of this study emphasize that in the future, clinics participating in ExPAND would benefit from education around how FQHCs can provide mifepristone for abortion care while complying with federal funding restrictions.
IMPLICATIONS STATEMENT: Learning collaboratives like ExPAND Mifepristone can help prepare primary care clinics to provide mifepristone. Clinicians and staff describe a clear benefit of mifepristone integration to their patient populations. Participants report mifepristone integration aligns with clinic values around patient-centered care and improved access to care.
Full text links
Related Resources
Trending Papers
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.Cardiovascular Diabetology 2024 November 15
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app